{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:07:41Z","timestamp":1792624061967,"version":"4.5.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Neurosurg Jl"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease remains a progressive and debilitating neurodegenerative disorder with limited therapeutic options that can modify disease progression. While conventional treatments like levodopa alleviate motor symptoms, they often fall short in addressing long-term neurodegeneration and may lead to significant side effects. Recent advances in regenerative medicine have highlighted the potential of combining stem cell therapy with Brain-Derived Neurotrophic Factor (BDNF) enhancement as a synergistic approach to restore dopaminergic function and promote neuronal survival. Stem cells not only offer the capacity to replace lost neurons but can also serve as delivery vectors for sustained BDNF expression, amplifying neuroprotective effects through Tropomyosin receptor kinase B-mediated signaling pathways. Preclinical studies in animal models demonstrate that this combined strategy enhances motor recovery, reduces neuroinflammation, and promotes neural circuit integration. As the field progresses, this dual therapy holds great promise for transforming the future management of Parkinson\u2019s disease by offering both symptomatic relief and disease modification.<\/jats:p>","DOI":"10.1186\/s41016-025-00415-5","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:13:11Z","timestamp":1762420391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergy between stem cell therapy and brain-derived neurotrophic factor (BDNF) in Parkinson\u2019s disease: a mini-review of combined neuroregenerative strategies"],"prefix":"10.1186","volume":"11","author":[{"given":"Jonny","family":"Jonny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid Devina","family":"Larasati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenesa Amabel","family":"Sunjaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Faried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"10","key":"415_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.neurol.2017.12.003","volume":"174","author":"A Alexoudi","year":"2018","unstructured":"Alexoudi A, Alexoudi I, Gatzonis S. Parkinson\u2019s disease pathogenesis, evolution and alternative pathways: a review. Rev Neurol (Paris). 2018;174(10):699\u2013704. https:\/\/doi.org\/10.1016\/j.neurol.2017.12.003.","journal-title":"Rev Neurol (Paris)"},{"key":"415_CR2","unstructured":"Zafar S, Yaddanapudi S. Parkinson disease. Natl Libr Med. 2023;1:227\u201331. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470193\/"},{"key":"415_CR3","doi-asserted-by":"publisher","unstructured":"V\u00e1radi C. Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms. Biology (Basel). 2020;9(5):103. https:\/\/doi.org\/10.3390\/biology9050103. PMID: 32438686; PMCID: PMC7285080.","DOI":"10.3390\/biology9050103"},{"issue":"September","key":"415_CR4","first-page":"1","volume":"15","author":"R Morimoto","year":"2023","unstructured":"Morimoto R, Iijima M, Okuma Y, Suzuki K, Yoshii F, Nogawa S, et al. Associations between non-motor symptoms and patient characteristics in Parkinson\u2019s disease: a multicenter cross-sectional study. Front Aging Neurosci. 2023;15(September):1\u201310.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"415_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm15050172","volume":"15","author":"L Pe\u00f1a-Zelayeta","year":"2025","unstructured":"Pe\u00f1a-Zelayeta L, Delgado-Minjares KM, Villegas-Rojas MM, Le\u00f3n-Arcia K, Santiago-Balmaseda A, Andrade-Guerrero J, et al. Redefining Non-Motor Symptoms in Parkinson\u2019s Disease. J Pers Med. 2025;15(5):1\u201335.","journal-title":"J Pers Med"},{"key":"415_CR6","doi-asserted-by":"publisher","unstructured":"Peng S, Liu P, Wang X, Li K. Global, regional and national burden of Parkinson's disease in people over 55 years of age: a systematic analysis of the global burden of disease study, 1991-2021. BMC Neurol. 2025;25(1):178. https:\/\/doi.org\/10.1186\/s12883-025-04191-8. PMID: 40269818; PMCID: PMC12016353.","DOI":"10.1186\/s12883-025-04191-8"},{"issue":"8","key":"415_CR7","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00702-017-1686-y","volume":"124","author":"OB Tysnes","year":"2017","unstructured":"Tysnes OB, Storstein A. Epidemiology of Parkinson\u2019s disease. J Neural Transm. 2017;124(8):901\u20135.","journal-title":"J Neural Transm"},{"issue":"4","key":"415_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2024-095610","volume":"15","author":"M Li","year":"2025","unstructured":"Li M, Ye X, Huang Z, Ye L, Chen C. Global burden of Parkinson\u2019s disease from 1990 to 2021: a population-based study. BMJ Open. 2025;15(4):1\u201310.","journal-title":"BMJ Open"},{"key":"415_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.776847","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s disease in 204 countries\/territories from 1990 to 2019. Front Public Health. 2021. https:\/\/doi.org\/10.3389\/fpubh.2021.776847.","journal-title":"Front Public Health"},{"key":"415_CR10","unstructured":"Rebecca G. Understanding stem cell therapy in Parkinson\u2019s disease treatment | APDA. Apdaparkinson. 2018;7\u201311. Available from: https:\/\/www.apdaparkinson.org\/article\/understanding-stem-cell-therapy-in-parkinsons-disease-treatment\/"},{"issue":"3","key":"415_CR11","first-page":"1","volume":"15","author":"T Pardo-Moreno","year":"2023","unstructured":"Pardo-Moreno T, Garc\u00eda-Morales V, Suleiman-Martos S, Rivas-Dom\u00ednguez A, Mohamed-Mohamed H, Ramos-Rodr\u00edguez JJ, et al. Current Treatments and New. Tentative Therapies for Parkinson\u2019s Disease Pharmaceutics. 2023;15(3):1\u201324.","journal-title":"Tentative Therapies for Parkinson\u2019s Disease Pharmaceutics"},{"issue":"6","key":"415_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"key":"415_CR13","unstructured":"NIA. Parkinson S Disease | Symptoms and Treatments of Parkinson S Disease. 2022;1\u20137. Available from: https:\/\/www.apollohospitals.com\/patient-care\/health-and-lifestyle\/diseases-and-conditions\/parkinson-s-disease\/"},{"issue":"4","key":"415_CR14","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/mdc3.12755","volume":"6","author":"N Afentou","year":"2019","unstructured":"Afentou N, Jarl J, Gerdtham UG, Saha S. Economic evaluation of interventions in Parkinson\u2019s disease: a systematic literature review. Mov Disord Clin Pract. 2019;6(4):282\u201390.","journal-title":"Mov Disord Clin Pract"},{"key":"415_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04484-x","author":"F Wang","year":"2023","unstructured":"Wang F, Sun Z, Peng D, Gianchandani S, Le W, Boltze J, et al. Cell-therapy for Parkinson\u2019s disease: a systematic review and meta-analysis. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04484-x.","journal-title":"J Transl Med"},{"issue":"3","key":"415_CR16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000438701","volume":"62","author":"MD Staudt","year":"2016","unstructured":"Staudt MD, Di Sebastiano AR, Xu H, Jog M, Schmid S, Foster P, et al. Advances in neurotrophic factor and cell-based therapies for Parkinson\u2019s disease: a mini-review. Gerontology. 2016;62(3):371\u201380.","journal-title":"Gerontology"},{"key":"415_CR17","unstructured":"APDA. Parkinson\u2019s Disease & End of Life. New York; 2022. Available from: https:\/\/www.apdaparkinson.org\/article\/death-parkinsons-disease-3\/"},{"key":"415_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21031170","author":"E Palasz","year":"2020","unstructured":"Palasz E, Wysocka A, Gasiorowska A, Chalimoniuk M, Niewiadomski W, Niewiadomska G. BDNF as a promising therapeutic agent in Parkinson\u2019s disease. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21031170.","journal-title":"Int J Mol Sci"},{"key":"415_CR19","unstructured":"Stoker TB, Greenland JC, editors. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018. PMID: 30702835."},{"key":"415_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jnc.13691","volume":"139","author":"S Sveinbjornsdottir","year":"2016","unstructured":"Sveinbjornsdottir S. The clinical symptoms of Parkinson\u2019s disease. J Neurochem. 2016;139:318\u201324.","journal-title":"J Neurochem"},{"key":"415_CR21","unstructured":"WPP. Classification of Parkinsonism. Toronto; 2016. Available from: https:\/\/pdprogram.org\/classification-of-parkinsonism\/"},{"issue":"1","key":"415_CR22","first-page":"1","volume":"1","author":"F Gaillard","year":"2018","unstructured":"Gaillard F, Sharma R. Parkinson disease. Radiol Ref Artic. 2018;1(1):1\u201313.","journal-title":"Radiol Ref Artic"},{"issue":"6","key":"415_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11910-024-01339-w","volume":"24","author":"JR Deliz","year":"2024","unstructured":"Deliz JR, Tanner CM, Gonzalez-Latapi P. Epidemiology of Parkinson\u2019s disease: an update. Curr Neurol Neurosci Rep. 2024;24(6):163\u201379.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"415_CR24","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s44286-025-00219-5","volume":"2","author":"G Chen","year":"2025","unstructured":"Chen G, Tat T, Zhou Y, Duan Z, Zhang J, Scott K, et al. Neural network-assisted personalized handwriting analysis for Parkinson\u2019s disease diagnostics. Nat Chem Eng. 2025;2(6):358\u201368.","journal-title":"Nat Chem Eng"},{"issue":"1","key":"415_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42484-025-00286-0","volume":"7","author":"G Cattan","year":"2025","unstructured":"Cattan G, Olmos J, Chauhan Y, Mart\u00ednez F. Parkinson disease classification: a comparison of quantum and RBF kernels using support vector machine. Quantum Mach Intell. 2025;7(1):1\u20135.","journal-title":"Quantum Mach Intell"},{"issue":"1","key":"415_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12880-024-01364-8","volume":"24","author":"H Li","year":"2024","unstructured":"Li H, Yang Z, Qi W, Yu X, Wu J, Li H. Parkinson\u2019s image detection and classification based on deep learning. BMC Med Imaging. 2024;24(1):187. https:\/\/doi.org\/10.1186\/s12880-024-01364-8.","journal-title":"BMC Med Imaging"},{"issue":"8","key":"415_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3233\/JPD-239005","volume":"13","author":"R Bhidayasiri","year":"2023","unstructured":"Bhidayasiri R, Kalia LV, Bloem BR. Tackling Parkinson\u2019s disease as a global challenge. J Parkinsons Dis. 2023;13(8):1277\u201380.","journal-title":"J Parkinsons Dis"},{"key":"415_CR28","doi-asserted-by":"crossref","unstructured":"Pereira GM, Teixeira-dos-Santos D, Soares NM, Marconi GA, Friedrich DC, Saffie Awad P, et al. A systematic review and meta-analysis of the prevalence of Parkinson\u2019s disease in lower to upper-middle-income countries. npj Park Dis. 2024;10(1):1\u201312.","DOI":"10.1038\/s41531-024-00779-y"},{"issue":"9","key":"415_CR29","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamaneurol.2022.1783","volume":"79","author":"N Schiess","year":"2022","unstructured":"Schiess N, Cataldi R, Okun MS, Fothergill-Misbah N, Dorsey ER, Bloem BR, et al. Six action steps to address global disparities in Parkinson disease: a World Health Organization priority. JAMA Neurol. 2022;79(9):929\u201336.","journal-title":"JAMA Neurol"},{"key":"415_CR30","doi-asserted-by":"publisher","DOI":"10.1159\/000542606","author":"Q Yang","year":"2024","unstructured":"Yang Q, Chang X, Li S, Li X, Kang C, Yuan W, et al. Disease burden of Parkinson\u2019s disease in Asia and its 34 countries and territories from 1990 to 2021: findings from the global burden of disease study 2021. Neuroepidemiology. 2024. https:\/\/doi.org\/10.1159\/000542606.","journal-title":"Neuroepidemiology"},{"key":"415_CR31","first-page":"1","volume":"5","author":"Q Zhong","year":"2022","unstructured":"Zhong Q. Trends in prevalence cases and disability - adjusted life - years of Parkinson\u2019s disease: findings from the Global Burden of Disease Study 2019. Neuroepidemiology. 2022;5:1\u20137.","journal-title":"Neuroepidemiology"},{"key":"415_CR32","doi-asserted-by":"publisher","unstructured":"Titova N, Chaudhuri KR. Personalized medicine and nonmotor symptoms in Parkinson\u2019s disease. 1st ed. Vol. 134, International Review of Neurobiology. Elsevier Inc.; 2017. 1257\u20131281 p. Available from: https:\/\/doi.org\/10.1016\/bs.irn.2017.05.015","DOI":"10.1016\/bs.irn.2017.05.015"},{"issue":"8","key":"415_CR33","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2174\/1570159X20666220315163856","volume":"21","author":"DJV Wamelen","year":"2022","unstructured":"Wamelen DJV, Rukavina K, Podlewska AM, Chaudhuri KR. Advances in the pharmacological and non-pharmacological management of non-motor symptoms in Parkinson\u2019s disease: an update since 2017. Curr Neuropharmacol. 2022;21(8):1786\u2013805.","journal-title":"Curr Neuropharmacol"},{"issue":"8","key":"415_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a009258","volume":"2","author":"DW Dickson","year":"2012","unstructured":"Dickson DW. Parkinson\u2019 s disease and parkinsonism in. Cold Spring,Med, Harb Perspect. 2012;2(8):1\u201315.","journal-title":"Cold Spring,Med, Harb Perspect"},{"key":"415_CR35","doi-asserted-by":"publisher","unstructured":"Gigu\u00e8re N, Burke Nanni S, Trudeau LE. On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease. Front Neurol. 2018;9:455. https:\/\/doi.org\/10.3389\/fneur.2018.00455. PMID: 29971039; PMCID: PMC6018545.","DOI":"10.3389\/fneur.2018.00455"},{"key":"415_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnsyn.2022.1002960","volume":"14","author":"CR Gerfen","year":"2023","unstructured":"Gerfen CR. Segregation of D1 and D2 dopamine receptors in the striatal direct and indirect pathways: an historical perspective. Front Synaptic Neurosci. 2023;14:1\u201323.","journal-title":"Front Synaptic Neurosci"},{"issue":"9996","key":"415_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3.","journal-title":"Lancet"},{"issue":"1","key":"415_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44194-022-00015-w","volume":"1","author":"Z Ye","year":"2022","unstructured":"Ye Z. Mapping neuromodulatory systems in Parkinson\u2019s disease: lessons learned beyond dopamine. Curr Med [Internet]. 2022;1(1):1\u201311. https:\/\/doi.org\/10.1007\/s44194-022-00015-w.","journal-title":"Curr Med [Internet]"},{"issue":"1","key":"415_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA Lewitt","year":"2015","unstructured":"Lewitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64\u201372.","journal-title":"Mov Disord"},{"key":"415_CR40","first-page":"1","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Prim. 2017;3:1\u201321.","journal-title":"Nat Rev Dis Prim"},{"key":"415_CR41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jnc.13750","volume":"139","author":"W Oertel","year":"2016","unstructured":"Oertel W, Schulz JB. Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem. 2016;139:325\u201337.","journal-title":"J Neurochem"},{"key":"415_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou KL, Stacy M, Simuni T, Miyasaki J, Oertel WH, Sethi K, et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: What have we learned over 40 years? Parkinsonism Relat Disord. 2018;51:9\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.001.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"415_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","volume":"75","author":"T M\u00fcller","year":"2015","unstructured":"M\u00fcller T. Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease. Drugs. 2015;75(2):157\u201374.","journal-title":"Drugs"},{"issue":"9","key":"415_CR44","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s40263-019-00661-z","volume":"33","author":"F Carbone","year":"2019","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson\u2019s disease: efficacy and safety of current and new formulations. CNS Drugs. 2019;33(9):905\u201318. https:\/\/doi.org\/10.1007\/s40263-019-00661-z.","journal-title":"CNS Drugs"},{"key":"415_CR45","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41582-020-00426-z","volume":"17","author":"JK Krauss","year":"2021","unstructured":"Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, et al. Technology of deep brain stimulation: current status and future directions. Nat Rev Neurol. 2021;17:75\u201387.","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"415_CR46","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/mds.28599","volume":"36","author":"FAP Nijhuis","year":"2021","unstructured":"Nijhuis FAP, Esselink R, de Bie RMA, Groenewoud H, Bloem BR, Post B, et al. Translating evidence to advanced Parkinson\u2019s disease patients: a systematic review and meta-analysis. Mov Disord. 2021;36(6):1293\u2013307.","journal-title":"Mov Disord"},{"issue":"s1","key":"415_CR47","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-202104","volume":"10","author":"JM Dijk","year":"2020","unstructured":"Dijk JM, Espay AJ, Katzenschlager R, De Bie RMA. The choice between advanced therapies for Parkinson\u2019s disease patients: why, what, and when? J Parkinsons Dis. 2020;10(s1):S65-73.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"415_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01987-1","volume":"29","author":"R Rahimi Darehbagh","year":"2024","unstructured":"Rahimi Darehbagh R, Seyedoshohadaei SA, Ramezani R, Rezaei N. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024;29(1):386. https:\/\/doi.org\/10.1186\/s40001-024-01987-1.","journal-title":"Eur J Med Res"},{"issue":"7378","key":"415_CR49","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10648","volume":"480","author":"S Kriks","year":"2012","unstructured":"Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z, et al. Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD. Nature. 2012;480(7378):547\u201351.","journal-title":"Nature"},{"issue":"3","key":"415_CR50","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.stemcr.2014.01.013","volume":"2","author":"D Doi","year":"2014","unstructured":"Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y, et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Reports. 2014;2(3):337\u201350. https:\/\/doi.org\/10.1016\/j.stemcr.2014.01.013.","journal-title":"Stem Cell Reports"},{"issue":"6","key":"415_CR51","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.14336\/AD.2022.0312","volume":"13","author":"X Zeng","year":"2022","unstructured":"Zeng X, Qin H. Stem cell transplantation for Parkinson\u2019s disease: current challenges and perspectives. Aging Dis. 2022;13(6):1652\u201363.","journal-title":"Aging Dis"},{"issue":"1","key":"415_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.14802\/jmd.22141","volume":"16","author":"Y Cha","year":"2023","unstructured":"Cha Y, Park TY, Leblanc P, Kim KS. Current status and future perspectives on stem cell-based therapies for Parkinson\u2019s disease. Journal of Movement Disorders. 2023;16(1):22\u201341.","journal-title":"Journal of Movement Disorders"},{"key":"415_CR53","doi-asserted-by":"publisher","unstructured":"Poliwoda S, Noor N, Downs E, Schaaf A, Cantwell A, Ganti L, Kaye AD, Mosel LI, Carroll CB, Viswanath O, Urits I. Stem cells: a comprehensive review of origins and emerging clinical roles in medical practice. Orthop Rev (Pavia). 2022;14(3):37498. https:\/\/doi.org\/10.52965\/001c.37498. PMID: 36034728; PMCID: PMC9404248.","DOI":"10.52965\/001c.37498"},{"issue":"4","key":"415_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.2174\/1570159X20666220327212414","volume":"21","author":"A Unnisa","year":"2022","unstructured":"Unnisa A, Dua K, Kamal MA. Mechanism of mesenchymal stem cells as a multitarget disease- modifying therapy for Parkinson\u2019s disease. Curr Neuropharmacol. 2022;21(4):988\u20131000.","journal-title":"Curr Neuropharmacol"},{"key":"415_CR55","unstructured":"Porsiana MD, Arimbawa IK. Terapi Stem Cell untuk Penyakit Parkinson. Cermin Dunia Kedokt. 2020;47(3):212\u20136. Available from: https:\/\/cdkjournal.com\/index.php\/CDK\/article\/view\/356"},{"issue":"21","key":"415_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21218060","volume":"21","author":"Z Liu","year":"2020","unstructured":"Liu Z, Cheung HH. Stem cell-based therapies for Parkinson disease. Int J Mol Sci. 2020;21(21):1\u201317.","journal-title":"Int J Mol Sci"},{"key":"415_CR57","unstructured":"Brigham MG. Clinical trial tests novel stem-cell treatment for Parkinson\u2019s disease. Mass General Brigham Patient Care. 2025;1\u20135. Available from: https:\/\/www.massgeneralbrigham.org\/en\/about\/newsroom\/press-releases\/clinical-trial-novel-stem-cell-treatment-for-parkinsons"},{"issue":"1","key":"415_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1400-1","volume":"4","author":"MH Fu","year":"2015","unstructured":"Fu MH, Li CL, Lin HL, Chen PC, Calkins MJ, Chang YF, et al. Stem cell transplantation therapy in Parkinson\u2019s disease. Springerplus. 2015;4(1):1\u20138.","journal-title":"Springerplus"},{"issue":"1","key":"415_CR59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21776\/ub.mnj.2017.003.01.7","volume":"3","author":"G Gunawan","year":"2017","unstructured":"Gunawan G, Dalhar M, Kurniawan SN. Parkinson and stem cell therapy. MNJ (Malang Neurology Journal). 2017;3(1):39\u201346.","journal-title":"MNJ (Malang Neurology Journal)"},{"issue":"20","key":"415_CR60","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1915872","volume":"382","author":"JS Schweitzer","year":"2020","unstructured":"Schweitzer JS, Song B, Herrington TM, Park TY, Lee N, Ko S, et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson\u2019s disease. N Engl J Med. 2020;382(20):1926\u201332.","journal-title":"N Engl J Med"},{"issue":"8064","key":"415_CR61","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature. 2025;641(8064):971\u20137. https:\/\/doi.org\/10.1038\/s41586-025-08700-0.","journal-title":"Nature"},{"issue":"8064","key":"415_CR62","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s41586-025-08845-y","volume":"641","author":"V Tabar","year":"2025","unstructured":"Tabar V, Sarva H, Lozano AM, Fasano A, Kalia SK, Yu KKH, et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson\u2019s disease. Nature. 2025;641(8064):978\u201383.","journal-title":"Nature"},{"key":"415_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104061","volume":"3","author":"YL Peng","year":"2024","unstructured":"Peng YL, Chen J, Hu H, Liu W, Liang W, Wang J. Research progress of cell treatment strategy in Parkinson\u2019s disease. Neuroscience Applied. 2024;3:104061. https:\/\/doi.org\/10.1016\/j.nsa.2024.104061.","journal-title":"Neuroscience Applied"},{"key":"415_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2019.10.634","volume":"405","author":"SP Adisti","year":"2019","unstructured":"Adisti SP, Subagya S, Wibowo S, Mauleka RG. Stem cells therapy for Parkinson\u2019s disease: an update review. J Neurol Sci. 2019;405:107.","journal-title":"J Neurol Sci"},{"issue":"3","key":"415_CR65","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00441-023-03806-1","volume":"393","author":"X Geng","year":"2023","unstructured":"Geng X, Zou Y, Li J, Li S, Qi R, Yu H, et al. BDNF alleviates Parkinson\u2019s disease by promoting STAT3 phosphorylation and regulating neuronal autophagy. Cell Tissue Res. 2023;393(3):455\u201370. https:\/\/doi.org\/10.1007\/s00441-023-03806-1.","journal-title":"Cell Tissue Res"},{"issue":"11","key":"415_CR66","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/jnr.24488","volume":"97","author":"V Scheper","year":"2019","unstructured":"Scheper V, Schwieger J, Hamm A, Lenarz T, Hoffmann A. BDNF-overexpressing human mesenchymal stem cells mediate increased neuronal protection in vitro. J Neurosci Res. 2019;97(11):1414\u201329.","journal-title":"J Neurosci Res"},{"key":"415_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-04073-9","author":"ST Ekrani","year":"2024","unstructured":"Ekrani ST, Mahmoudi M, Haghmorad D, Kheder RK, Hatami A, Esmaeili SA. Manipulated mesenchymal stem cell therapy in the treatment of Parkinson\u2019s disease. Stem Cell Res Ther. 2024. https:\/\/doi.org\/10.1186\/s13287-024-04073-9.","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"415_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.17219\/acem\/154955","volume":"32","author":"Z Chen","year":"2023","unstructured":"Chen Z, Zhang H. A meta-analysis on the role of brain-derived neurotrophic factor in Parkinson\u2019s disease patients. Adv Clin Exp Med. 2023;32(3):285\u201395.","journal-title":"Adv Clin Exp Med"},{"issue":"2","key":"415_CR69","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1590\/1516-4446-2016-1980","volume":"39","author":"LA de Azeredo","year":"2017","unstructured":"de Azeredo LA, De Nardi T, Levandowski ML, Tractenberg SG, Kommers-Molina J, Wieck A, et al. The brain-derived neurotrophic factor (BDNF) gene val66met polymorphism affects memory performance in older adults. Rev Bras Psiquiatr. 2017;39(2):90\u20134.","journal-title":"Rev Bras Psiquiatr"},{"key":"415_CR70","first-page":"9","volume":"126","author":"BL Hempstead","year":"2015","unstructured":"Hempstead BL. Brain-derived neurotrophic factor: three ligands, many actions. Trans Am Clin Climatol Assoc. 2015;126:9\u201319.","journal-title":"Trans Am Clin Climatol Assoc"},{"issue":"2","key":"415_CR71","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155\u201375.","journal-title":"Pharmacol Ther"},{"issue":"6","key":"415_CR72","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.5114\/aoms.2015.56342","volume":"11","author":"S Bathina","year":"2015","unstructured":"Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164\u201378.","journal-title":"Arch Med Sci"},{"issue":"4","key":"415_CR73","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4103\/1673-5374.205084","volume":"12","author":"TB Sampaio","year":"2017","unstructured":"Sampaio TB, Savall AS, Gutierrez MEZ, Pinton S. Neurotrophic factors in Alzheimer\u2019s and Parkinson\u2019s diseases: implications for pathogenesis and therapy. Neural Regen Res. 2017;12(4):549\u201357.","journal-title":"Neural Regen Res"},{"issue":"10","key":"415_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jcmm.18368","volume":"28","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, AlAseeri AA, et al. BDNF\/TrkB activators in Parkinson\u2019s disease: a new therapeutic strategy. J Cell Mol Med. 2024;28(10):1\u201316.","journal-title":"J Cell Mol Med"},{"issue":"05","key":"415_CR75","doi-asserted-by":"publisher","first-page":"252","DOI":"10.26502\/jppd.2572-519X0025","volume":"01","author":"M Angoa-Perez","year":"2017","unstructured":"Angoa-Perez M, Anneken JH, Kuhn D. The role of brain-derived neurotrophic factor in the pathophysiology of psychiatric and neurological disorders. J Psychiatry Psychiatr Disord. 2017;01(05):252\u201369.","journal-title":"J Psychiatry Psychiatr Disord"},{"issue":"20","key":"415_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207777","volume":"21","author":"L Colucci-D\u2019amato","year":"2020","unstructured":"Colucci-D\u2019amato L, Speranza L, Volpicelli F. Neurotrophic factor bdnf, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci. 2020;21(20):1\u201329.","journal-title":"Int J Mol Sci"},{"key":"415_CR77","doi-asserted-by":"publisher","unstructured":"Han F, Baremberg D, Gao J, Duan J, Lu X, Zhang N, et al. Development of stem cell-based therapy for Parkinson\u2019s disease. Transl Neurodegener. 2015;4(16):1\u201313. Available from: https:\/\/doi.org\/10.1186\/s40035-015-0039-8","DOI":"10.1186\/s40035-015-0039-8"},{"issue":"5","key":"415_CR78","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2174\/1381612822666161208120422","volume":"23","author":"D Tome","year":"2017","unstructured":"Tome D, Fonseca CP, Campos FL, Baltazar G. Role of neurotrophic factors in Parkinson\u2019 s disease. Curr Pharm Des. 2017;23(5):809\u201338.","journal-title":"Curr Pharm Des"},{"key":"415_CR79","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3233\/JPD-212662","volume":"11","author":"S Jarrin","year":"2021","unstructured":"Jarrin S, Hakami A, Newland B. Growth factor therapy for Parkinson \u2019 s disease: alternative delivery systems. J Parkinsons Dis. 2021;11:229\u201336.","journal-title":"J Parkinsons Dis"},{"issue":"June","key":"415_CR80","first-page":"1","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Deng J, Liu Y, Li W, Nie X. FGF, mechanism of action, role in Parkinson \u2019 s disease, and therapeutics. Front Pharmacol. 2021;12(June):1\u201317.","journal-title":"Front Pharmacol"},{"key":"415_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fncel.2021.682597","volume":"15","author":"O Bondarenko","year":"2021","unstructured":"Bondarenko O, Saarma M, Widmer HR. Neurotrophic factors in Parkinson \u2019 s disease: clinical trials, open challenges and nanoparticle-mediated delivery to the brain. Front Cell Neurosci. 2021;15:1\u201318.","journal-title":"Front Cell Neurosci"},{"issue":"8","key":"415_CR82","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1177\/1877718X241301041","volume":"14","author":"RA Barker","year":"2024","unstructured":"Barker RA, Saarma M, Svendsen CN, Morgan C, Whone A, Fiandaca MS, et al. Neurotrophic factors for Parkinson \u2019 s disease: current status, progress, and remaining questions. Conclusions from a 2023 workshop. J Parkinsons Dis. 2024;14(8):1659\u201376.","journal-title":"J Parkinsons Dis"},{"key":"415_CR83","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neulet.2016.05.032","volume":"626","author":"S Salemi","year":"2016","unstructured":"Salemi S, Baktash P, Rajaei B, Noori M, Amini H, Shamsara M, et al. Efficient generation of dopaminergic-like neurons by overexpression of Nurr1 and Pitx3 in mouse induced pluripotent stem cells. Neurosci Lett. 2016;626:126\u201334. https:\/\/doi.org\/10.1016\/j.neulet.2016.05.032.","journal-title":"Neurosci Lett"},{"key":"415_CR84","doi-asserted-by":"publisher","unstructured":"Chung S, Leung A, Han B soo, Chang M yoon, Moon J il, Kim C hyung, et al. Article Wnt1-lmx1a Forms a Novel Autoregulatory Loop and Controls Midbrain Dopaminergic Differentiation Synergistically with the SHH-FoxA2 Pathway. Stem Cell. 2009;5(6):646\u201358. Available from: https:\/\/doi.org\/10.1016\/j.stem.2009.09.015","DOI":"10.1016\/j.stem.2009.09.015"},{"issue":"136","key":"415_CR85","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1242\/dev.029769","volume":"540","author":"FMJ Jacobs","year":"2009","unstructured":"Jacobs FMJ, Van ES, Van Der LAJA, Von OL, Burbach JPH, Smidt MP. Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through release of SMRT-mediated repression. Development. 2009;540(136):531\u201340.","journal-title":"Development"},{"key":"415_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231710138","author":"J Gordon","year":"2022","unstructured":"Gordon J, Lockard G, Monsour M, Alayli A, Choudhary H, Borlongan CV. Sequestration of inflammation in Parkinson\u2019s disease via stem cell therapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231710138.","journal-title":"Int J Mol Sci"},{"key":"415_CR87","doi-asserted-by":"publisher","unstructured":"Zhong Z, Chen A, Fa Z, Ding Z, Xiao L, Wu G, et al. Bone marrow mesenchymal stem cells upregulate PI3K\/Akt pathway and down-regulate NF-\u03baB pathway by secreting glial cell-derived neurotrophic factors to regulate microglial polarization and alleviate deafferentation pain in rats. Neurobiol Dis. 2020;143(February):104945. Available from: https:\/\/doi.org\/10.1016\/j.nbd.2020.104945","DOI":"10.1016\/j.nbd.2020.104945"},{"issue":"5","key":"415_CR88","doi-asserted-by":"publisher","first-page":"973","DOI":"10.4103\/1673-5374.385305","volume":"19","author":"FR Fusco","year":"2024","unstructured":"Fusco FR, Paldino E. Is GDNF to Parkinson s disease what BDNF is to Huntington s disease? Neural Regen Res. 2024;19(5):973\u20134.","journal-title":"Neural Regen Res"},{"key":"415_CR89","doi-asserted-by":"publisher","unstructured":"Zhao Z, Sun J, Liu Y, Liu M, Tong D. Association of brain-derived neurotrophic factor in blood and cerebrospinal fluid with Parkinson's disease and non-motor symptoms of Parkinson's disease: a systematic review and meta-analysis of 6655 participants. Front Aging Neurosci. 2025;17:1620172. https:\/\/doi.org\/10.3389\/fnagi.2025.1620172. PMID: 41049535; PMCID: PMC12492986.","DOI":"10.3389\/fnagi.2025.1620172"},{"key":"415_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14030194","author":"DGM Kaagman","year":"2024","unstructured":"Kaagman DGM, van Wegen EEH, Cignetti N, Rothermel E, Vanbellingen T, Hirsch MA. Effects and mechanisms of exercise on brain-derived neurotrophic factor (BDNF) levels and clinical outcomes in people with Parkinson\u2019s disease: a systematic review and meta-analysis. Brain Sci. 2024. https:\/\/doi.org\/10.3390\/brainsci14030194.","journal-title":"Brain Sci"},{"key":"415_CR91","doi-asserted-by":"publisher","unstructured":"Jiang Z, Wang J, Sun G, Feng M. BDNF-modified human umbilical cord mesenchymal stem cells-derived dopaminergic-like neurons improve rotation behavior of Parkinson \u2019 s disease rats through neuroprotection and anti-neuroinflammation. Mol Cell Neurosci. 2022;123(October):103784. https:\/\/doi.org\/10.1016\/j.mcn.2022.103784","DOI":"10.1016\/j.mcn.2022.103784"},{"issue":"3","key":"415_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/brainsci15030252","volume":"15","author":"AA Singh","year":"2025","unstructured":"Singh AA, Katiyar S, Song M. Phytochemicals targeting BDNF signaling for treating neurological disorders. Brain Sci. 2025;15(3):1\u201328.","journal-title":"Brain Sci"},{"key":"415_CR93","unstructured":"Cusabio. Cusabio Technology. 2025. p. 1 Neurotrophin signaling pathway. Available from: https:\/\/www.cusabio.com\/pathway\/Neurotrophin-signaling-pathway.html?srsltid=AfmBOoqwILv4_lezoYHMgrU6l3OzR8xuXo8dd0sxJtcl_byp3kAc9Qwu"},{"issue":"13","key":"415_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms26136416","volume":"26","author":"MS Khan","year":"2025","unstructured":"Khan MS, Nasiripour S, Bopassa JC. Parkinson disease signaling pathways, molecular mechanisms, and potential therapeutic strategies: a comprehensive review. Int J Mol Sci. 2025;26(13):1\u201332.","journal-title":"Int J Mol Sci"},{"key":"415_CR95","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010257","author":"W Jin","year":"2020","unstructured":"Jin W. Regulation of BDNF-TrkB signaling and potential therapeutic strategies for Parkinson\u2019s disease. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm9010257.","journal-title":"J Clin Med"},{"key":"415_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnmol.2024.1009404","volume":"17","author":"G Moya-Alvarado","year":"2024","unstructured":"Moya-Alvarado G, Valero-Pe\u00f1a X, Aguirre-Soto A, Bustos FJ, Lazo OM, Bronfman FC. PLC-\u03b3-Ca2+ pathway regulates axonal TrkB endocytosis and is required for long-distance propagation of BDNF signaling. Front Mol Neurosci. 2024;17:1\u201316.","journal-title":"Front Mol Neurosci"},{"issue":"10","key":"415_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms26104926","volume":"26","author":"M Mitrovic","year":"2025","unstructured":"Mitrovic M, Selakovic D, Jovicic N, Ljujic B, Rosic G. BDNF\/proBDNF interplay in the mediation of neuronal apoptotic mechanisms in neurodegenerative diseases. Int J Mol Sci. 2025;26(10):1\u201345.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"415_CR98","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.4103\/NRR.NRR-D-24-00771","volume":"20","author":"LX Yi","year":"2025","unstructured":"Yi LX, Woon HR, Saw G, Zeng L, Tan EK, Zhou ZD. Induced pluripotent stem cell\u2013related approaches to generate dopaminergic neurons for Parkinson\u2019s disease. Neural Regen Res. 2025;20(11):3193\u2013206.","journal-title":"Neural Regen Res"},{"issue":"4","key":"415_CR99","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.nano.2017.02.006","volume":"13","author":"AJ Espadas-Alvarez","year":"2017","unstructured":"Espadas-Alvarez AJ, Bannon MJ, Orozco-Barrios CE, Escobedo-Sanchez L, Ayala-Davila J, Reyes-Corona D, et al. Regulation of human GDNF gene expression in nigral dopaminergic neurons using a new doxycycline-regulated NTS-polyplex nanoparticle system. Nanomedicine. 2017;13(4):1363\u201375. https:\/\/doi.org\/10.1016\/j.nano.2017.02.006.","journal-title":"Nanomedicine"},{"issue":"1","key":"415_CR100","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11427-012-4424-6","volume":"56","author":"SY Wang","year":"2013","unstructured":"Wang SY, Ren P, Guan YQ, Zou CL, Fu LL, Zhang Y. Inducible regulation of GDNF expression in human neural stem cells. Sci China Life Sci. 2013;56(1):32\u20139.","journal-title":"Sci China Life Sci"},{"issue":"MAY","key":"415_CR101","first-page":"1","volume":"6","author":"R Greco","year":"2015","unstructured":"Greco R, Oliveira G, Lupo Stanghellini MT, Vago L, Bondanza A, Peccatori J, et al. Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol. 2015;6(MAY):1\u201313.","journal-title":"Front Pharmacol"},{"issue":"10","key":"415_CR102","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1523\/JNEUROSCI.23-10-04164.2003","volume":"23","author":"G Okoye","year":"2003","unstructured":"Okoye G, Zimmer J, Sung J, Gehlbach P, Deering T, Nambu H, et al. Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage. J Neurosci. 2003;23(10):4164\u201372.","journal-title":"J Neurosci"}],"container-title":["Chinese Neurosurgical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-025-00415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41016-025-00415-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41016-025-00415-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:12:02Z","timestamp":1762423922000},"score":1,"resource":{"primary":{"URL":"https:\/\/cnjournal.biomedcentral.com\/articles\/10.1186\/s41016-025-00415-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["415"],"URL":"https:\/\/doi.org\/10.1186\/s41016-025-00415-5","relation":{},"ISSN":["2057-4967"],"issn-type":[{"value":"2057-4967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}